Publicacions en què col·labora amb JULIO EDUARDO NUÑEZ VILLOTA (36)

2024

  1. Congestion as a crucial factor determining albuminuria in patients with cardiorenal disease

    Clinical Kidney Journal, Vol. 17, Núm. 6

  2. High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure

    Scientific Reports, Vol. 14, Núm. 1

  3. Urinary Cell Cycle Arrest Biomarkers and Diuretic Efficiency in Acute Heart Failure

    CardioRenal Medicine, Vol. 14, Núm. 1, pp. 261-269

2023

  1. Assessment of filling pressures and fluid overload in heart failure: an updated perspective

    Revista Espanola de Cardiologia, Vol. 76, Núm. 1, pp. 47-57

  2. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

    Journal of Clinical Medicine, Vol. 12, Núm. 1

  3. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  4. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  5. Kidney function changes in acute heart failure: a practical approach to interpretation and management

    Clinical Kidney Journal, Vol. 16, Núm. 10, pp. 1587-1599

  6. Peritoneal and Urinary Sodium Removal in Refractory Congestive Heart Failure Patients Included in an Ambulatory Peritoneal Dialysis Program: Valuable for Monitoring the Course of the Disease

    CardioRenal Medicine, Vol. 13, Núm. 1, pp. 211-220

  7. Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure

    Revista Espanola de Cardiologia, Vol. 76, Núm. 2, pp. 121-123

  8. Practical approaches to building up a cardiorenal clinic

    Clinical Kidney Journal, Vol. 16, Núm. 5, pp. 780-792

  9. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry

    Revista Espanola de Cardiologia

  10. Sex differences in Cardiorenal Syndrome: Insights from CARDIOREN Registry

    Current Heart Failure Reports, Vol. 20, Núm. 3, pp. 157-167

  11. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

  12. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

    Journal of Cardiac Failure, Vol. 29, Núm. 5, pp. 849-854

  13. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

    Frontiers in Cardiovascular Medicine, Vol. 10

2022

  1. Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes

    Journal of Clinical Medicine, Vol. 11, Núm. 11

  2. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure

    European Journal of Heart Failure, Vol. 24, Núm. 11, pp. 2108-2117

  3. Current state of cardiorenal units in Spain

    REC: CardioClinics, Vol. 57, Núm. 4, pp. 299-302

  4. Long-Term Prognostic Impact of Estimated Glomerular Filtration Rate on Admission in Patients Hospitalized for Acute Heart Failure

    CardioRenal Medicine, Vol. 12, Núm. 4, pp. 179-188